Pain may be an important factor to consider in inflammatory bowel disease patients troubled by fatigue

United European Gastroenterology Journal 2017, Vol. 5(5) 687-693 © Author(s) 2016 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav DOI: 10.1177/2050640616674654 journals.sagepub.com/home/ueg

SAGE

UNITED EUROPEAN GASTROENTEROLOGY

Lars-Petter Jelsness-Jørgensen¹, Svein-Oskar Frigstad², Bjørn Moum³, Tore Grimstad⁴, Randi Opheim³, Jørgen Jahnsen⁵ and Tomm Bernklev⁶

Abstract

Background: Pain has been associated with fatigue in many chronic diseases, but data are not available for inflammatory bowel disease (IBD). The aim of this study was to investigate whether fatigue is associated with pain in IBD after adjusting for the relevant covariates.

Methods: Participants were recruited from nine hospitals in the south-eastern and western part of Norway. Socio-demographic variables were self-reported by patients. Disease activity was assessed by disease activity indices and faecal calprotectin. Patient-reported outcomes (PROs) were collected using the Fatigue Questionnaire (FQ), Brief Pain Inventory (BPI), Hospital Anxiety and Depression Scale (HADS) and Basic Nordic Sleep Questionnaire.

Results: From a total of 452 invited patients, 414 (91.6%) provided written informed consent. After excluding any missing data, 408 total patients were included in the analyses (ulcerative colitis = 180 and Crohn's disease = 228). In the crude analysis, substantial and chronic fatigue were associated with increased pain intensity regardless of the diagnosis. However, when controlling for relevant covariates in the ANCOVA, the differences in pain intensity among patients with and without substantial or chronic fatigue were insignificant. The Cohen's *d* effect size was small to moderate (>0.20) in patients with chronic fatigue.

Conclusions: Despite a tendency of elevated pain intensity scores among patients with fatigue, these differences were insignificant after controlling for the relevant covariates. However, based on Cohen's effect size, these differences may be of clinical importance in a subset of patients.

Keywords

Fatigue, pain, Crohn's disease, ulcerative colitis, patient-reported outcome

Received: 9 June 2016; accepted: 20 September 2016

Introduction

Inflammatory bowel disease (IBD) consists of ulcerative colitis (UC) and Crohn's disease (CD) and is characterised by chronic, recurrent inflammation of the gastrointestinal (GI) tract.¹ In UC, the inflammation is located in the colonic and rectal mucosa, whereas in CD, any part of the GI tract may be affected. Common IBD symptoms include abdominal pain, tenesmus and diarrhoea, either with or without blood, pus and mucus.²

Fatigue is a frequently reported symptom in patients with IBD.³ Several definitions of fatigue exist, which indicates a lack of consensus. However, the recent literature defines fatigue as, 'an overwhelming, debilitating, and sustained sense of exhaustion that decreases

¹Østfold University College, Department of Health Sciences/Østfold Hospital Trust, Department of Gastroenterology, Fredrikstad, Norway

²Vestre Viken Hospital Trust, Department of Gastroenterology/Østfold Hospital Trust, Department of Internal Medicine, Norway

Corresponding author:

³Oslo University Hospital, Department of Gastroenterology/University of Oslo, Oslo, Norway

⁴Stavanger University Hospital, Department of Gastroenterology, Stavanger, Norway

⁵Akershus University Hospital, Department of Gastroenterology, Lørenskog, Norway; University of Oslo, Institute of Clinical Medicine, Oslo, Norway
⁶Telemark Hospital Trust, Department of Research/University of Oslo, Skien, Norway

Lars-Petter Jelsness-Jørgensen, Postboks 700, 1757 Halden, Østfold University College, Department of Health Sciences/Østfold Hospital Trust, Department of Gastroenterology, Fredrikstad, Norway. Email: lars.p.jelsness-jorgensen@hiof.no

one's ability to carry out daily activities, including the ability to work effectively and to function at one's usual level in family and social roles'.⁴ In most cases, fatigue is influenced by disease activity, but studies have also revealed that these symptoms are prevalent even when patients are deemed to be in remission.^{5–8} Prior studies also revealed that factors such as anxiety, depression and decreased levels of haemoglobin are associated with increased fatigue.³ Fatigue is viewed by IBD patients as one of their most burdensome symptoms, and it is associated with increased worry and impaired health-related quality of life (HRQoL).^{9–12} In addition, there are reports of a gap between health care personnel's knowledge and understanding of the complexity of fatigue and the impact that these symptoms have on IBD.¹³

In addition to fatigue, pain is one major symptom that occurs in IBD.¹⁴ The latter is related not only to abdominal discomfort, which is caused by inflammation or strictures with subsequent bowel distension, but also non-inflammatory joint pain and pain caused by arthritis.¹⁵ In other chronic illnesses, such as rheumatoid arthritis (RA) and multiple sclerosis (MS), increased pain has been associated with more fatigue.^{16,17} Although an association between pain and fatigue has been demonstrated in other patient populations, no such data are available for IBD. Based on input from members of the Norwegian Crohn's and Colitis Association, we hypothesised that pain might also be a potential unexplored factor of importance for fatigue symptoms in IBD. Investigating the potential association between fatigue and pain in IBD may be helpful in planning how to manage or alleviate fatigue among these patients.

Consequently, the primary aim of this study was to investigate whether fatigue symptoms are associated with increased pain in IBD. The secondary aim was to investigate whether controlling for disease activity, depression and sleep problems could influence these scores.

Materials and methods

Participants were recruited from IBD outpatient clinics at nine hospitals in the south-eastern and western part of Norway from March 2013 to April 2014. The inclusion criteria were: >17 years of age, a verified diagnosis of IBD (based on endoscopic, laboratory and histological findings, i.e. the Lennard-Jones criteria),¹⁸ the ability to read Norwegian, and written informed consent.

Data collection

After patients had consented to participate in the study, a standardised inclusion procedure was followed at

each centre. This allowed clinical, socio-demographic, questionnaire and laboratory data to be collected at the hospital during inclusion.

While the socio-demographic variables included age, gender, smoking status, and marital and educational status, the disease activity was assessed by the Simple Clinical Colitis Activity Index (SCCAI) and the Simplified Crohn's Disease Activity Index (SCDAI).^{19,20} To measure faecal calprotectin, stool samples were delivered in person at the outpatient clinic and sent by mail to Gas-Cal-Lab[©], Oslo University Hospital, where they were stored at -20° C until ready for extraction (Roche Diagnostics GmbH[®]). The phenotypic classification was conducted according to the Montreal classification.

Questionnaires

The Fatigue Questionnaire (FQ). The FQ was developed by Chalder et al.²¹ and has been previously validated in several settings including IBD.^{7,22} The scale scores of the FQ were scored on a dichotomised scale (0 = better than usual and no more than usual, 1 = worse than usual and much worse than usual). Based on prior studies and the general consensus, substantial fatigue was defined as a dichotomised FQ score >4, whereas chronic fatigue (CF) was defined as a dichotomised FQ score >4, and in addition, a duration ≥ 6 months.^{21,23}

The Brief Pain Inventory (BPI). Developed by Cleeland and Ryan,²⁴ the BPI was designed to measure (a) the subjective intensity of pain and (b) the impairment caused by pain. The pain intensity section of the BPI consists of four items that are scored from 0 (no pain) to 10 (worst possible pain). A pain severity score is calculated from the mean of the four pain intensity items.²⁴ Recently, the BPI was evaluated in IBD.²⁵

Hospital Anxiety and Depression Scale (HADS). Depression was measured using the depression subscale of the Hospital Anxiety and Depression Scale (HADS).²⁶ HADS is a self-assessment instrument that is divided into two scales: (A) measuring anxiety and (D) depression. Each scale has seven items that are scored on a four-point Likert scale (0–3); the higher the score, the greater the level of anxiety and depression. The Likert scale has been widely used to describe the prevalence of anxiety and depression in IBD.

Basic Nordic Sleep Questionnaire. Sleep problems were measured using the Basic Nordic Sleep Questionnaire item on sleep quality in the last three months. The item is scored on a five-point Likert scale, where a higher score indicates increased sleep problems.²⁷

Statistical analyses. To assess patient characteristics, we used descriptive analysis, frequencies and the χ^2 test. The means and standard deviations were used to express normally distributed variables, whereas the medians and interquartile range (IQR) were used to express non-normally distributed variables. To investigate potential associations between fatigue and pain, an analysis of variance (ANOVA) was used. To correct the model for relevant covariates hypothesised to influence fatigue and pain, the following factors were entered as covariates in the analysis of covariance (ANCOVA): gender, disease activity index score, C-reactive protein (CRP), haemoglobin, ferritin and calprotectin levels, depression, anxiety and sleep problems. The data on fatigue and pain are presented as: (a) crude scores and (b) scores adjusted for the previously presented factors (estimated marginal means). Cohen's d was used to calculate clinical significance.²⁸ Operational definitions of 0.2, 0.5 and 0.8 were categorised as small, medium and large effect sizes, respectively.²⁸ All of the tests were two sided with a 5% significance level and performed using Predictive Analytics Software (PASW) version 22.0 (SPSS Inc, 233 S. Wacker Drive, Chicago, IL, USA).

Ethics. Participation in the study was based on written informed consent and performed in accordance with the principles of the revised Helsinki Declaration. Approval was obtained from the Regional Ethics Committee (reference number: 2012/845/REK Sør-Øst A).

Results

A total of 452 patients were eligible and invited to participate in the study. Four hundred and fourteen patients (91.6%) gave written informed consent. Four of these patients were excluded because the missing data exceeded 50% of the complete dataset. This left the total number included in analysis at 410 patients, out of whom 230 were diagnosed with CD and 180 with UC. Baseline characteristics of the patients included are presented in Table 1. While all of the 410 patients completed the BPI, there were two CD patients with missing FQs. Consequently, 408 patients were included in both pain and fatigue (UC = 180 and CD = 228). There were no significant differences in gender or age between patients either declining participation, being excluded due to missing values or those included in the analyses (data not shown).

Out of the 408 patients who had evaluable data on both the BPI and FQ, substantial fatigue (SF) was reported in 90/180 (50%) of UC patients and in 104/228 (45.6%) of CD patients. CF was reported in 52/180 (28.9%) of UC patients and in 65/228 (28.5%) of CD

 Table 1. Socio-demographic and clinical data according to diagnosis.

	UC (<i>n</i> = 180)	CD (<i>n</i> = 230)	p value
Age (median (IQR)	40 (31-50)	40 (31-49)	0.92
Gender			
Female	87	114	
Male	93	116	0.81
Time since diagnosis (median (IQR))	6 (2-12)	11 (5-22)	<0.001
SCCAI total score (median (IQR))	3 (1-5)		
SCDAI total score (median (IQR))		4 (2-7)	
Calprotectin (median (IQR))	59 (27-257)	97 (37-280)	0.30
C-reactive protein (median (IQR))	2 (0-4.7)	2 (0-6)	0.70
HADS-A (median (IQR))	6 (4-8)	5 (3-8)	0.22
HADS-D (median (IQR))	3 (1-5)	3 (1-6)	0.63
Sleep problems (median (IQR))	2 (2-3)	2 (2-3)	0.21
UC extent ^a			
E1 – Proctitis	20 (11.1%)		
E2 - Left-sided colitis	58 (32.2%)		
E3 - Extensive colitis	102 (56.7%)		
CD localisation ^a			
L1 - Terminal ileum		75 (32.6%)	
L2 – Colon		47 (20.4%)	
L3 - Ileocolon		76 (33.0%)	
L4 – Upper Gl		32 (13.9%)	
CD upper GI-modification			
L1 + L4		8 (25.0%)	
L2 + L4		6 (18.8%)	
L3 + L4		18 (56.3%)	
CD behaviour ^a			
B1 - Non penetrating/ non-stricturing		117 (50.9%)	
B2 - Stricturing		83 (36.1%)	
B3 - Penetrating		30 (13.0%)	

UC: ulcerative colitis; CD: Crohn's disease; GI: gastrointestinal; SD: standard deviation: IQR: interquartile range; SCCAI: Simple Clinical Colitis Activity Index; HADS: Hospital Anxiety and Depression Scale; SCDAI: Simplified Crohn's Disease Activity Index, ^aMontreal Classification. Figures are the mean and standard deviation in brackets if not otherwise noted.

patients. There were no statistically significant differences in the occurrence of substantial- or CF between the diagnostic groups.

The anxiety, depression and disease activity index scores were significantly associated with substantial

	Ulcerative colitis ($n = 180$)								
	SF	SF				CF			
	No n = 90	Yes n = 90	p value	Cohen's <i>d</i>	No n = 128	Yes n = 52	p value	Cohen's <i>d</i>	
BPI Pain Intensity - mean (SD)	5.4 (5.7)	10.9 (8.1)	<0.001	-0.78	6.6 (6.4)	11.9 (8.7)	<0.001	-0.69	
	Crohn's disease $(n = 228)$								
	SF				CF				
	No n = 124	Yes n = 104	p value	Cohen's <i>d</i>	No n = 163	Yes n = 65	p value	Cohen's d	
BPI Pain Intensity - mean (SD)	6.0 (5.6)	9.3 (7.0)	<0.001	-0.52	6.5 (5.9)	10.2 (7.0)	<0.001	-0.57	

Table 2. Crude pain intensity scores among patients reporting substantial (SF) or chronic fatigue (CF).

BPI: Brief Pain Inventory; SD: standard deviation, Cohen's d: operational definitions of 0.2, 0.5 and 0.8 regarded as small, medium and large effect size, respectively.

fatigue in UC and substantial as well as CF in CD (Mann Whitney U, p < 0.001). In UC patients, CF was associated with depression and an increased disease activity score (Mann-Whitney U, p < 0.001). A higher level of sleep problems was associated with both substantial and CF, regardless of diagnosis (Mann-Whitney U, p < 0.001). Neither age, nor the levels of haemoglobin, ferritin, CRP or calprotectin were significantly associated with substantial or CF in UC or CD.

A total of 323 out of 408 patients delivered a stool sample for the measurement of faecal calprotectin (79.2%, UC 147/180, CD 176/228). There were no statistically significant differences in calprotectin levels between the diagnostic groups (Table 1). In UC, the correlation between the SCCAI total score and CRP was insignificant, whereas a significant correlation was observed between the SCCAI and calprotectin (0.38, p < 0.001). In CD, the SCDAI total score was not correlated with either CRP or calprotectin.

Fatigue and pain intensity

Patients reporting substantial and CF had significantly higher pain intensity scores compared to those without fatigue, regardless of the diagnosis (Table 2). After controlling for covariates (age, disease activity index scores, CRP, calprotectin, ferritin, haemoglobin, anxiety, depression and sleep problems), there was a numerical tendency towards increased pain intensity levels in patients with fatigue. However, these differences were insignificant, regardless of the diagnosis (Table 3).

Calculating Cohen's *d* effect size revealed that differences in pain intensity scores were moderate to large in

the ANOVA (Table 2). Following ANCOVA, a small effect size remained among patients with CF, regardless of the diagnosis (Table 3).

Discussion

Compared to IBD patients without fatigue, patients with substantial and/or CF had significantly increased pain intensity scores. However, after adjustment for relevant covariates, differences in pain intensity among these patients was insignificant. However, in patients with CF, the effect sizes remained small to moderate.

Until recently, fatigue in IBD was investigated only to a limited extent. However, following a review by van Langenberg and Gibson in 2010,²⁹ a substantial body of literature has been published to study prevalence, predictors and the impact of fatigue in IBD.^{3,9,30} In IBD, higher levels of fatigue have most frequently been associated with increased disease activity,^{3,7,8,31} but numerous other physical and psychological factors that may influence fatigue have been identified.^{6,7,31,32} Prior studies are also conflicting in regard to some of these factors.^{30,32} Although the interest in research has increased, IBD fatigue still remains inadequately investigated.

Pain has been reported to be a frequent complaint and concern among IBD patients and is also related to disease activity (e.g. measured by SCDAI).^{14,33} In this regard, we hypothesised that pain symptoms could be associated with fatigue. Our findings reveal that crude pain intensity scores were twice as high in UC patients with SF compared to those without, whereas in CD, the score was one-third higher in patients with SF.

	Ulcerative colitis ($n = 142$)							
	SF			CF				
	No n = 73	Yes n = 69	p value	Cohen's d	No n = 105	Yes n = 37	p value	Cohen's d
BPI Pain Intensity – estimated marginal mean (SD)	7.8 (6.0)	9.0 (8.2)	0.37	-0.16	8.0 (6.7)	9.6 (9.0)	0.27	-0.20
	Crohn's disease ($n = 170$)							
	SF			CF				
	No n = 93	Yes n = 77	p value	Cohen's d	No n = 120	Yes n = 50	p value	Cohen's d
BPI Pain Intensity – estimated marginal mean (SD)	7.0 (5.6)	7.8 (6.5)	0.46	-0.13	6.9 (5.7)	8.4 (6.7)	0.16	-0.24

Table 3. Pain intensity scores calculated as the estimated marginal means in the analysis of covariance^a (ANCOVA). Scores are presented according to the presence of substantial or chronic fatigue.

^aThe following covariates appear in the model: age, disease activity index total score, calprotectin, C-reactive protein, ferritin, haemoglobin, sleep problems, HADS anxiety and depression. Only patients with complete data for all parameters included as covariates appear in the model. BPI: Brief Pain Inventory; SD: standard deviation, HADS: Hospital Anxiety and Depression Scale; Cohen's *d*: operational definitions of 0.2, 0.5 and 0.8 regarded as small, medium and large effect size, respectively

Moreover, when comparing patients with and without CF, the differences in pain intensity further increased regardless of the diagnosis. Consequently, these results seem to align with prior studies in e.g. RA^{16,34} and MS.¹⁷ Indeed, in RA, studies have indicated that pain may be a stronger predictor of fatigue than disease activity.³⁵ Several causal explanations for this association have been proposed. On one hand, fatigue could be caused by prolonged pain exposure and dealing with pain is energy consuming. On the other hand, fatigue can cause more pain due to less ability to deal with pain.³⁵ However, in RA, longitudinal studies have not indicated that one precedes the other, but that pain and fatigue seem to be synchronous.³⁴

However, given prior identification of the factors associated with IBD fatigue,³ a potential association between pain and fatigue cannot be based merely on crude scores. Consequently, taking into account potential covariates, such as age, disease activity, depression, anxiety, sleep problems, haemoglobin and ferritin levels, seems inevitable.^{4,7,8,32} Furthermore, calprotectin has been shown to be a more specific marker of intestinal inflammation than CRP.36 Hence, CRP and calprotectin may be measuring something quite different. Therefore, both were entered as covariates in the ANCOVA. Our findings indicated that after controlling for these potential covariates, patients with fatigue tended to have higher pain intensity levels. However, the levels of pain intensity scores were not statistically significantly different from those patients not reporting fatigue. Moreover, these findings confirm the

importance of taking into account factors such as disease activity, depressive symptoms and sleep problems when investigating fatigue.

Even though one strength of the current study is the large sample of IBD patients recruited from multiple centres, a limitation may be related to the fact that the results in this study are based merely on hospital outpatients. The latter may cause speculations as to whether the patients recruited were those with more active disease and more frequent hospital visits. However, it is important to emphasise, even though such a bias cannot be ruled out, that the vast majority of Norwegian IBD patients are found in specialised hospital clinics. Another limitation is that the Basic Nordic Sleep Questionnaire has not previously been validated in IBD. Moreover, the pain intensity scale of the BPI is a generic pain scale and does not differentiate between different pain locations. Consequently, it is impossible to assess whether pain intensity in this population is mainly driven by abdominal or extraintestinal pain. Although plasma ferritin is in equilibrium with body stores, we did not measure serum iron and total iron-binding capacity (TIBC), which could have provided us a clearer picture of the iron status in this population.

In conclusion, after adjusting for relevant covariates, the statistically significant association between pain intensity and fatigue in IBD disappeared. However, judged by Cohen's effect size, these differences may not be trivial in a subset of patients. Thus, despite the lack of statistical significance, we believe that an assessment of pain may be important in patients troubled by fatigue. Future studies need to examine whether pain interventions may have a beneficial effect on fatigue.

Declaration of conflicting interests

None declared.

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

References

- 1. Ponder A and Long MD. A clinical review of recent findings in the epidemiology of inflammatory bowel disease. *Clin Epidemiol* 2013; 5: 237–247.
- Srinath A, Young E and Szigethy E. Pain management in patients with inflammatory bowel disease: Translational approaches from bench to bedside. *Inflamm Bowel Dis* 2014; 20: 2433–2449.
- Czuber-Dochan W, Ream E and Norton C. Review article: Description and management of fatigue in inflammatory bowel disease. *Aliment Pharmacol Ther* 2013; 37: 505–516.
- Dantzer R, Heijnen CJ, Kavelaars A, et al. The neuroimmune basis of fatigue. *Trends Neurosci* 2014; 37: 39–46.
- Graff LA, Clara I, Walker JR, et al. Changes in fatigue over 2 years are associated with activity of inflammatory bowel disease and psychological factors. *Clin Gastroenterol Hepatol* 2013; 11: 1140–1146.
- Minderhoud IM, Oldenburg B, van Dam PS, et al. High prevalence of fatigue in quiescent inflammatory bowel disease is not related to adrenocortical insufficiency. *Am J Gastroenterol* 2003; 98: 1088–1093.
- Jelsness-Jørgensen LP, Bernklev T, Henriksen M, et al. Chronic fatigue is more prevalent in patients with inflammatory bowel disease than in healthy controls. *Inflamm Bowel Dis* 2011; 17: 1564–1572.
- Bager P, Befrits R, Wikman O, et al. Fatigue in outpatients with inflammatory bowel disease is common and multifactorial. *Aliment Pharmacol Ther* 2012; 35: 133–141.
- 9. Farrell D, McCarthy G and Savage E. Self-reported symptom burden in individuals with inflammatory bowel disease. *J Crohns Colitis* 2016; 10: 315–322.
- Jelsness-Jørgensen LP, Bernklev T, Henriksen M, et al. Chronic fatigue is associated with increased diseaserelated worries and concerns in inflammatory bowel disease. *World J Gastroenterol* 2012; 18: 445–452.
- 11. Jelsness-Jørgensen LP, Bernklev T, Henriksen M, et al. Chronic fatigue is associated with impaired health-related quality of life in inflammatory bowel disease. *Aliment Pharmacol Ther* 2011; 33: 106–114.
- Opheim R, Fagermoen MS, Bernklev T, et al. Fatigue interference with daily living among patients with inflammatory bowel disease. *Qual Life Res* 2014; 23: 707–717.

- Czuber-Dochan W, Norton C, Bredin F, et al. Healthcare professionals' perceptions of fatigue experienced by people with IBD. J Crohns Colitis 2014; 8: 835–844.
- Bielefeldt K, Davis B and Binion DG. Pain and inflammatory bowel disease. *Inflamm Bowel Dis* 2009; 15: 778–788.
- PalmØ, Bernklev T, Moum B, et al. Non-inflammatory joint pain in patients with inflammatory bowel disease is prevalent and has a significant impact on health related quality of life. *J Rheumatol* 2005; 32: 1755–1759.
- Nikolaus S, Bode C, Taal E, et al. Fatigue and factors related to fatigue in rheumatoid arthritis: A systematic review. *Arthritis Care Res* 2013; 65: 1128–1146.
- O'Connor AB, Schwid SR, Herrmann DN, et al. Pain associated with multiple sclerosis: Systematic review and proposed classification. *Pain* 2008; 137: 96–111.
- Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989; 170: 2–6; discussion 16–19.
- 19. Walmsley RS, Ayres RC, Pounder RE, et al. A simple clinical colitis activity index. *Gut* 1998; 43: 29–32.
- Harvey RF and Bradshaw JM. A simple index of Crohn's-disease activity. *Lancet* 1980; 1: 514.
- Chalder T, Berelowitz G, Pawlikowska T, et al. Development of a fatigue scale. J Psychosom Res 1993; 37: 147–153.
- Jelsness-Jørgensen LP. The Fatigue Questionnaire has a good test-retest profile in IBD. *Aliment Pharmacol Ther* 2012; 35: 621–622.
- Loge JH, Ekeberg O and Kaasa S. Fatigue in the general Norwegian population: Normative data and associations. *J Psychosom Res* 1998; 45: 53–65.
- Cleeland CS and Ryan KM. Pain assessment: Global use of the Brief Pain Inventory. *Ann Acad Med Singapore* 1994; 23: 129–138.
- 25. Jelsness-Jørgensen LP, Moum B, Grimstad T, et al. Validity, reliability, and responsiveness of the Brief Pain Inventory in inflammatory bowel disease. *Can J Gastroenterol Hepatol* 2016; 2016: 5624261.
- Zigmond AS and Snaith RP. The Hospital Anxiety and Depression Scale. *Acta Psychiatr Scand* 1983; 67: 361–370.
- Herrmann C. International experiences with the Hospital Anxiety and Depression Scale – a review of validation data and clinical results. J Psychosom Res 1997; 42: 17–41.
- 28. Cohen J. Statistical power analysis for the behavioral sciences. Hillsdale, N.J.: Laurence Erlbaum, 1988.
- van Langenberg DR and Gibson PR. Systematic review: Fatigue in inflammatory bowel disease. *Aliment Pharmacol Ther* 2010; 32: 131–143.
- Grimstad T, Norheim KB, Isaksen K, et al. Fatigue in newly diagnosed inflammatory bowel disease. J Crohns Colitis 2015; 9: 725–730.
- Graff LA, Vincent N, Walker JR, et al. A populationbased study of fatigue and sleep difficulties in inflammatory bowel disease. *Inflamm Bowel Dis* 2011; 17: 1882–1889.
- 32. Romberg-Camps MJ, Bol Y, Dagnelie PC, et al. Fatigue and health-related quality of life in inflammatory bowel

disease: Results from a population-based study in the Netherlands: The IBD-South Limburg cohort. *Inflamm Bowel Dis* 2010; 16: 2137–2147.

- 33. Docherty MJ, Jones RC 3rd and Wallace MS. Managing pain in inflammatory bowel disease. *Gastroenterol Hepatol (N Y)* 2011; 7: 592–601.
- 34. van Dartel SA, Repping-Wuts JW, van Hoogmoed D, et al. Association between fatigue and pain in rheumatoid

arthritis: Does pain precede fatigue or does fatigue precede pain? *Arthritis Care Res* 2013; 65: 862–869.

- 35. Pollard LC, Choy EH, Gonzalez J, et al. Fatigue in rheumatoid arthritis reflects pain, not disease activity. *Rheumatology (Oxford)* 2006; 45: 885–889.
- 36. Fengming Y and Jianbing W. Biomarkers of inflammatory bowel disease. *Dis Markers* 2014; 2014: 710915.